Partner Therapeutics’ Leukine Shows Promise for Alzheimer’s in New Study

Study findings published in Alzheimer's & Dementia: Translational Research and Clinical Interventions suggest Leukine® (sargramostim), a yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF), leads to significant reversal of cognitive impairment and normalizes blood-based biomarkers of dementia in patients with mild-to-moderate Alzheimer’s disease (AD).